French Polynesia vs Iceland: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
French Polynesia
0.0%
in 2024
Iceland
0.0%
in 2024
French Polynesia rank
168th
Iceland rank
168th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- French Polynesia
- Iceland
How they compare
French Polynesia currently reports 0.0% against 0.0% in Iceland, a difference of 0.0%.
Across all 10 years both countries report, Iceland has been ahead every year.
French Polynesia ranks 168th and Iceland ranks 168th of 247 countries.
Iceland has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | French Polynesia | Iceland | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.0% | 0.1% | 0.1% | Iceland |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, French Polynesia or Iceland?
- French Polynesia, at 0.0% against 0.0% in Iceland as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between French Polynesia and Iceland?
- 0.0%, with French Polynesia ahead.
- How many years of comparable data are there for French Polynesia and Iceland?
- 10 years are reported by both, from 2015 to 2024.
- How do French Polynesia and Iceland rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- French Polynesia ranks 168th and Iceland ranks 168th of 247 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.